| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Revenues | 30,564 | - | 25,488 | |
| Cost of revenues | 1,628 | - | 958 | |
| Selling and marketing | 15,328 | - | 13,699 | |
| Research and development | 2,363 | - | 2,775 | |
| General and administrative | 4,319 | - | 3,823 | |
| Loss on disposal of assets, net | -1 | - | - | |
| Total operating expenses | 23,639 | - | 21,255 | |
| Income from operations | 6,925 | - | 4,233 | |
| Change in fair value of warrant liability | 23 | - | 228 | |
| Interest income, net | - | - | 523 | |
| Other income (expense), net | 727 | - | -598 | |
| Income before income taxes | 7,629 | - | 3,930 | |
| Provision for income taxes | 1,693 | - | 1,074 | |
| Net income | 5,936 | 1,576 | 2,856 | |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent, total | - | 303 | - | |
| Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest | - | 1,879 | - | |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to noncontrolling interest | - | 104 | - | |
| Net income attributable to noncontrolling interest | 2,326 | 1,134 | 1,732 | |
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | - | 1,238 | - | |
| Comprehensive income (loss), net of tax, attributable to parent | - | 641 | - | |
| Net income attributable to common stockholders | 3,610 | - | 1,124 | |
| Earnings per share, basic | 0.04 | 0 | 0.01 | |
| Earnings per share, diluted | 0.03 | 0 | 0.01 | |
| Weighted average number of shares outstanding, diluted | 103,971,546 | 102,701,707 | 102,640,373 | |
| Weighted-average number of shares used in computing net income (loss) per share available to common stockholders, basic | 90,850,040 | 89,119,344 | 85,643,646 | |
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)